Lv4
730 积分 2021-04-27 加入
OP0095 Efficacy and safety of deucravacitinib up to week 52 from POETYK PsA-2: a multicenter, randomized, double-blind, placebo-controlled, phase 3 study in patients with psoriatic arthritis
16天前
已关闭
Correction to: Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)
1个月前
已完结
Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
1个月前
已完结
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?
1个月前
已完结
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update
1个月前
已完结
Strategies for targeting cytokines in inflammatory bowel disease
1个月前
已完结
Dual Therapy in Inflammatory Bowel Disease
1个月前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
1个月前
已完结
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
1个月前
已完结
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
1个月前
已完结
皖公网安备34019202002308
